ERBB2 and breast cancer: In Indonesia, a comparative study between young (≤40 years old) and elderly (≥60 years old) breast cancer patients showed that the former group had more positive lymph nodes, HER2/neu receptor positivity, adjuvant chemotherapy and tamoxifen use.